Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (177)	12/31/2001 9:46:29 AM
From: tuck	Respond to of 360

>>GAITHERSBURG, Md.--(BW HealthWire)--Dec. 31, 2001-- Gene Logic Inc. (Nasdaq:GLGC - news), a leading provider of biocontent and bioinformatics solutions, today announced it has extended the market reach of its GeneExpress® Suite product offering with the launch of a new product, GeneExpress® Reports. Derived from the larger GeneExpress® Suite, GeneExpress® Reports comprise a smaller, more focused view of comprehensive gene expression data and provide critical answers to specific questions keyed to individual genes of interest. These Reports are being offered at an entry-level price and constitute an additional product offering of unique value to the drug development and research communities. Simultaneous with the launch of this new product, Gene Logic also announced it has achieved initial commercial success with five biotechnology companies signing on as GeneExpress®Reports customers: Vertex Pharmaceuticals, Inc., Athersys, Inc., Proteologics, Inc., ZYCOS Inc. and an unnamed biopharmaceutical company whose name is being withheld at the company's request. GeneExpress® Reports provide comprehensive expression, genetic and clinical information from a wide range of normal and diseased tissue samples contained in Gene Logic's BioExpressTM Module, a data sub set of the GeneExpress® Suite. The Reports include a series of tabulations and graphs derived using the tools within the GeneExpress® Suite, such as e-NorthernTM algorithms. GeneExpress® Reports provide scientists with biological data, derived from human tissues, indicating levels of gene expression alterations under various diseased and normal conditions, as well as clinical parameters. This new pay-per-view product format enables researchers to access answers to their queries in a more expedited and focused manner. Typical pricing for GeneExpress® Reports will range from $25,000 to several hundred thousand dollars depending on the number of genes and tissue samples surveyed. Developed to expand the reach of Gene Logic's proprietary data and to serve a broader range of customers, GeneExpress® Reports can be swiftly delivered to customers because they are generated using pre-configured computational routines and rely on underlying data already resident in Gene Logic's proprietary GeneExpress® Suite of databases. ``We are very excited about both the launch and initial commercial success of GeneExpress® Reports,'' commented Mark D. Gessler, Chairman and CEO of Gene Logic. ``Clearly, the GeneExpress® Suite is providing a significant value proposition to our pharma and biotech customers. This new, targeted product will extend that value by appealing to a new customer base with different cost/value requirements. Our focus has always been on building valuable information products for researchers throughout the drug development community. GeneExpress® Reports and the five biotechnology customers who have purchased Reports is clear evidence of that directive. We look to add additional customers to this new product offering throughout calendar 2002.''<< snip "We're only making posts for Nigel . . . Nigel." Cheers (& apologies to Andy Partridge & and his band, XTC), Tuck